Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Harvard Business School
Baxter
Johnson and Johnson
Express Scripts

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

PROSTASCINT Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: PROSTASCINT
Patents:9
Applicants:1
BLAs:1

US Patents for PROSTASCINT

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28   Start Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28   Start Trial City of Hope (Duarte, CA) 2030-10-08 RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28   Start Trial AbbVie Inc. (North Chicago, IL) 2027-11-30 RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28   Start Trial biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) 2031-08-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for PROSTASCINT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122015000061 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
93138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
122016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
CA 2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
CA 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
300753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Baxter
Dow
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.